Table 2 Subscale and composite scores on the National Eye Institute Visual Function Questionnaire-25 for patients with ocular syphilis (n = 32 individuals) presented as mean ± standard deviation overall and for different clinical characteristics.
From: Vision-related quality of life in patients treated for ocular syphilis
Characteristic | Score | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General health | General vision | Ocular pain | Near activities | Distance activities | Social functioning | Mental health | Role difficulties | Dependency | Driving | Color vision | Peripheral vision | Composite | |
Overall, n = 32 (100%) | 66.7 ± 16.7 | 69.8 ± 20.0 | 84.8 ± 21.8 | 74.9 ± 23.1 | 75.2 ± 24.5 | 84.4 ± 24.9 | 60.9 ± 24.5 | 71.3 ± 29.3 | 82.8 ± 25.5 | 59.1 ± 39.6 | 89.1 ± 21.0 | 74.2 ± 27.3 | 75.5 ± 19.8 |
Gender, n (%) | |||||||||||||
Woman, 8 (25%) | 60.1 ± 18.2 | 72.5 ± 8.9 | 95.9 ± 26.3 | 71.8 ± 16.2 | 69.8 ± 20.3 | 81.2 ± 22.6 | 59.4 ± 27.8 | 75.0 ± 18.3 | 86.7 ± 16.2 | 56.7 ± 38.4 | 93.8 ± 17.7 | 75.0 ± 29.9 | 76.0 ± 15.9 |
Man, 24 (75%) | 68.8 ± 16.2 | 69.0 ± 22.6 | 84.4 ± 20.6 | 76.0 ± 25.2 | 77.0 ± 25.8 | 85.4 ± 26.0 | 61.5 ± 23.9 | 70.1 ± 32.4 | 81.5 ± 28.1 | 59.7 ± 40.9 | 87.5 ± 22.1 | 73.9 ± 27.1 | 75.3 ± 21.2 |
Age, n (%) | |||||||||||||
≤ 40 years, 11 (34%) | 74.4 ± 16.1 | 78.2 ± 12.7 | 86.6 ± 12.3 | 93.4 ± 6.2 | 91.4 ± 10.9 | 98.6 ± 3.2 | 76.8 ± 14.0 | 95.0 ± 7.8 | 98.9 ± 2.4 | 89.2 ± 11.8 | 97.7 ± 7.5 | 95.5 ± 10.1 | 91.0 ± 6.3 |
> 40 year, 21 (66%) | 62.7 ± 15.9 | 65.5 ± 22.0 | 83.9 ± 24.2 | 65.4 ± 22.9 | 66.8 ± 25.5 | 77.1 ± 28.1 | 52.6 ± 24.9 | 58.9 ± 29.0 | 74.3 ± 28.1 | 35.9 ± 37.8 | 84.5 ± 24.3 | 63.1 ± 26.9 | 67.3 ± 19.6 |
HIV infection, n (%) | |||||||||||||
Yes, 5 (15.6%) | 69.0 ± 21.7 | 65.0 ± 23.7 | 72.5 ± 16.3 | 79.2 ± 25.8 | 73.4 ± 22.6 | 81.7 ± 24.6 | 65.0 ± 20.3 | 75.0 ± 36.7 | 75.0 ± 39.8 | 68.8 ± 46.4 | 90.0 ± 22.4 | 75.0 ± 30.6 | 74.5 ± 23.5 |
No, 27 (84.4%) | 66.3 ± 16.1 | 70.7 ± 19.6 | 87.0 ± 22.1 | 74.2 ± 23.0 | 75.6 ± 25.2 | 85.0 ± 25.4 | 60.2 ± 25.4 | 70.6 ± 28.6 | 84.3 ± 22.8 | 57.0 ± 39.1 | 88.9 ± 21.2 | 74.1 ± 27.3 | 75.6 ± 19.5 |
Bilateral involvement, n (%) | |||||||||||||
Yes, 19 (59.4%) | 62.1 ± 16.7 | 70.8 ± 18.2 | 78.8 ± 27.7 | 75.2 ± 21.8 | 76.9 ± 19.2 | 93.7 ± 7.7 | 63.1 ± 20.4 | 74.5 ± 22.7 | 85.5 ± 19.2 | 65.4 ± 35.2 | 88.5 ± 19.4 | 71.2 ± 22.5 | 77.1 ± 14.0 |
No, 13 (40.6%) | 69.9 ± 16.5 | 69.2 ± 21.6 | 88.8 ± 16.1 | 74.8 ± 24.5 | 74.1 ± 28.0 | 78.2 ± 20.4 | 59.5 ± 27.4 | 69.1 ± 22.8 | 80.9 ± 29.4 | 56.3 ± 42.1 | 89.5 ± 22.5 | 76.3 ± 30.6 | 74.4 ± 23.2 |
Classification of uveitisa, n (%) | |||||||||||||
Posterior, 20 (62.5%) | 68.6 ± 19.1 | 67.5 ± 22.5 | 84.4 ± 24.3 | 73.5 ± 25.5 | 76.0 ± 26.6 | 87.9 ± 23.3 | 66.0 ± 22.4 | 74.7 ± 29.4 | 81.6 ± 29.6 | 66.7 ± 39.8 | 93.8 ± 17.9 | 73.8 ± 27.5 | 76.9 ± 20.8 |
Panuveitis, 11 (34.4%) | 63.4 ± 12.8 | 76.4 ± 12.7 | 86.4 ± 18.1 | 79.9 ± 17.8 | 78.8 ± 14.0 | 84.8 ± 17.0 | 55.9 ± 24.8 | 69.3 ± 27.9 | 86.4 ± 17.6 | 53.1 ± 36.4 | 84.1 ± 23.1 | 79.6 ± 24.5 | 76.5 ± 14.8 |
Initial BCVA, n (%) | |||||||||||||
> 20/50, 19 (59.4%) | 67.5 ± 16.2 | 72.4 ± 16.5 | 82.9 ± 24.7 | 78.1 ± 19.9 | 83.1 ± 19.0 | 95.2 ± 6.9 | 70.3 ± 17.7 | 81.9 ± 20.6 | 91.8 ± 16.9 | 72.6 ± 34.5 | 92.1 ± 16.8 | 80.3 ± 24.4 | 81.9 ± 14.0 |
≤ 20/50, 13 (40.6%) | 65.6 ± 18.1 | 66.1 ± 24.5 | 87.5 ± 16.9 | 70.4 ± 27.3 | 63.8 ± 27.6 | 68.6 ± 32.8 | 47.3 ± 27.2 | 55.7 ± 33.8 | 69.7 ± 30.6 | 37.9 ± 39.3 | 84.6 ± 26.1 | 65.4 ± 29.8 | 66.1 ± 23.5 |
Antibiotic treatment, n (%) | |||||||||||||
IV penicillin G, 19 (59.5%) | 66.4 ± 18.2 | 65.3 ± 23.2 | 83.6 ± 22.1 | 68.2 ± 26.5 | 69.0 ± 26.5 | 78.9 ± 29.4 | 57.4 ± 26.4 | 62.5 ± 33.2 | 77.3 ± 30.3 | 51.3 ± 44.1 | 85.5 ± 24.0 | 69.7 ± 30.7 | 70.3 ± 22.8 |
IV ceftriaxone, 13 (40.6%) | 67.2 ± 15.0 | 76.5 ± 12.0 | 86.5 ± 21.9 | 84.8 ± 12.1 | 84.3 ± 18.3 | 92.3 ± 13.8 | 66.2 ± 21.3 | 84.2 ± 16.3 | 90.9 ± 13.7 | 69.2 ± 32.2 | 94.2 ± 15.0 | 80.8 ± 20.8 | 82.9 ± 11.3 |
Corticosteroid treatment, n (%) | |||||||||||||
Yes, 21 (65.6%) | 68.0 ± 12.5 | 72.9 ± 15.1 | 88.1 ± 15.6 | 77.7 ± 19.8 | 79.0 ± 20.7 | 86.2 ± 24.1 | 61.9 ± 22.8 | 74.1 ± 26.1 | 89.6 ± 16.2 | 58.8 ± 39.5 | 91.7 ± 18.3 | 75.0 ± 26.2 | 78.0 ± 16.6 |
No, 11 (34.4%) | 64.4 ± 23.4 | 64.1 ± 27.0 | 78.4 ± 30.2 | 69.7 ± 28.6 | 68.0 ± 30.2 | 81.1 ± 27.4 | 59.1 ± 28.5 | 65.9 ± 35.4 | 69.8 ± 34.8 | 60.4 ± 45.8 | 84.1 ± 25.7 | 72.7 ± 30.5 | 70.6 ± 25.0 |
Final BCVA, n (%) | |||||||||||||
> 20/50, 26 (81.3%) | 68.2 ± 16.3 | 74.2 ± 15.3 | 85.1 ± 20.0 | 81.0 ± 18.9 | 82.2 ± 18.6 | 89.4 ± 17.7 | 67.7 ± 20.5 | 80.8 ± 21.6 | 89.7 ± 20.4 | 67.9 ± 34.3 | 93.3 ± 16.7 | 78.9 ± 24.2 | 81.2 ± 15.2 |
≤ 20/50, 6 (18.7%) | 60.4 ± 18.9 | 50.8 ± 28.0 | 83.3 ± 30.3 | 48.6 ± 22.0 | 45.0 ± 25.0 | 62.5 ± 39.7 | 31.7 ± 18.9 | 30.0 ± 22.5 | 53.1 ± 25.5 | 0.0 ± 0.0 | 70.8 ± 29.2 | 54.1 ± 33.2 | 50.5 ± 18.7 |
